Paclitaxel plus Oxalipliatin in the Treatment of iv Stage Non Small Lung Cancer

Abstract

Objective to evaluate the short term efficacy and side effect between paclitaxel plus Oxaliplatin regime and paclitaxel plus cisplatin regime. Methods 64 patients with iv stage non small lung caner were divided into the experiment group and the control group randomly. The total dose of paclitaxel were 135 mg/m^2in each cycle and in each group. The experiment group used oxaliplatin 130mg/ m^2, （intravenous infusion, d1）, four weeks for a cycle. The control group used cisplatin 75mg/m^2, （intravenous infusion, dl）, four weeks for a cycle. The two chemotherapy continued for two cycles. To evaluate the efficacy and safety after four weeks when the chemotherapy were finished. Resuls the overall response rate in experiment group was 46.9% for CR2, PR,3, SD,4, PD3, respectively, The overall response rate in control group was 43.8% for CR2, PR12, SD14, PD 4 The effective rate of experiment group is higher than that of control group, but without statistic significant different （P〉0.05）.The neural toxicity in experiment group is higher than fhat of control group（P〈0.05）.The nausea and vomiting in the control group is significant higher than that of experiment group（P〈0.05）.The side effect of blood in two group were similarly （P〉0.05）.Conclusion the chemotherapy of pacliaxel plus cisplatin and paclitaxel plus oxaliplatin were the nearly the same, but the latter with lower emesis, nausea and liver and renal toxicity, however it has higher neural toxicity. Key words: non-small lung cancer pacliaxel cisplatin oxalipliatin